GM-CSF can convert DCs in cancers to the pro-inflammatory phenotype with better antigen-presentation capabilities to cytotoxic T cells or to the tolerogenic phenotype that suppresses cytotoxic T cells at the expense of regulatory cells (32). The gene discussed is CSF2; the disease is cancer.